{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifnxm7anunbs6ex5oouhf2j7cbhvsj25k3kgy7p2b3mov77el723a",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mjzbihjthzr2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiffcj5fjoluliffhul3r455b6626dsw6dpiiknw42dq4typuz3fuu"
    },
    "mimeType": "image/jpeg",
    "size": 133910
  },
  "path": "/news/2026-04-early-myocarditis-onset-immunotherapy-treatment.html",
  "publishedAt": "2026-04-21T11:00:17.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in patients who experienced co-occurring myositis and myasthenia gravis, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.",
  "title": "Early myocarditis onset after immunotherapy may predict treatment-related fatality"
}